Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 14/20 | 0.48 |
| ▸ | CNR2 | P34972 | 11/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.47 |
| ▸ | FDFT1 | P37268 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5265141 | 0.80 | CNR1 (0.49) | CNR1CNR2FDFT1 | |
| SCHEMBL6432925 | 0.77 | CNR1 (0.55) | CNR1CNR2FDFT1 | |
| SCHEMBL5262773 | 0.77 | CNR1 (0.72) | CNR1CNR2FDFT1 | |
| SCHEMBL5262269 | 0.75 | CNR1 (0.63) | CNR1CNR2FDFT1 | |
| SCHEMBL5262379 | 0.75 | CNR1 (0.51) | CNR1CNR2FDFT1 | |
| SCHEMBL5261540 | 0.74 | CNR1 (0.60) | CNR1CNR2FDFT1 | |
| SCHEMBL5259904 | 0.74 | CNR1 (0.57) | CNR1CNR2FDFT1 | |
| SCHEMBL5262899 | 0.73 | CNR1 (0.50) | CNR1CNR2FDFT1 | |
| SCHEMBL5373379 | 0.73 | CNR1 (0.59) | CNR1CNR2FDFT1 | |
| SCHEMBL5262360 | 0.73 | CNR1 (0.52) | CNR1CNR2FDFT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1494997-A4 | SUBSTITUTED ARYL AMIDES | MERCK & CO INC (US) | 2007-04-11 | — | — | EP | claimed |
| JP-2005527586-A | — | — | 2005-09-15 | — | — | JP | claimed |
| US-20050154202-A1 | Substituted aryl amides | MERCK & CO., INC. | 2005-07-14 | — | — | US | claimed |
| EP-1494997-A1 | SUBSTITUTED ARYL AMIDES | Merck & Co., Inc. (US) | 2005-01-12 | — | — | EP | claimed |
| WO-2003087037-A1 | SUBSTITUTED ARYL AMIDES | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | claimed |
| EP-1494997-A4 | SUBSTITUTED ARYL AMIDES | MERCK & CO INC (US) | 2007-04-11 | — | — | EP | disclosed |
| US-20050154202-A1 | Substituted aryl amides | MERCK & CO., INC. | 2005-07-14 | — | — | US | disclosed |
| EP-1494997-A1 | SUBSTITUTED ARYL AMIDES | Merck & Co., Inc. (US) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003087037-A1 | SUBSTITUTED ARYL AMIDES | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154202-A1 | Substituted aryl amides | CNR1, CNR2, FAAH | CNR1 1/4885CNR2 2/4885ADORA3 1634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.